|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PD-L1+/CD8High type accounted for majority of EBV+ and MSI-high (MSI-H) GCs (92.0% and 66.7%, respectively), and genome analysis from public datasets demonstrated similar pattern.
|
28412752 |
2017 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer.
|
28794626 |
2017 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our study revealed that PD-L1 expression is associated with the corresponding immunoscore and that the immunoscore can be a relevant marker for the determination of the prognostic role of PD-L1 expression in MSI-H GCs.
|
28938605 |
2017 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study assessed the clinical significance of PD-L1 mRNA expression in blood specimens obtained from patients with gastric cancer.
|
29345842 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers.
|
29872566 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, we identified mutations associated with elevated PD-L1 expression that facilitate the development of better prognostic biomarkers for GC, and might offer insight into the underlying tumor biology.
|
30670970 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The clinical significance of PD-L1 in advanced gastric cancer is dependent on <i>ARID1A</i> mutations and ATM expression.
|
30221053 |
2018 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PD-L1-positive was seen in 8.8% of cases, with predominant expression in EBV-positive GC (P < 0.001).
|
29534305 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bioinformatics was used to explore the PD-L1-related genes in GC and propose a hypothesis.
|
29690901 |
2018 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer.
|
29034543 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PD-L1 Expression and CD8<sup>+</sup> T Cell Infiltration Predict a Favorable Prognosis in Advanced Gastric Cancer.
|
30003113 |
2018 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results highlights the need to assess both PDL1 expression in all tumor context and the characterization of the GC immune microenvironment.
|
29399387 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We compared IHC staining of PD-L1 in gastric cancer (GC) by using three commercially available antibody clones, and analyzed the correlation with the prognosis.
|
30463584 |
2018 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
RNA-seq data from The Cancer Genome Atlas revealed that expression of B7-H1, HDAC1-3, 6-8, and 10 and SIRT1, 3, 5, and 6 was higher, and expression of HDAC5 and SIRT4 was lower in GC compared to that in normal gastric tissues; that HDAC3 and HDAC1 expression level significantly correlated with B7-H1 in GC with a respective r value of 0.42 (p < 0.001) and 0.21 (p < 0.001).
|
30537988 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, the FDA in 2017 approved pembrolizumab for PD-L1-positive advanced gastric cancer in third-line and second-line hepatocellular therapy.
|
29542354 |
2018 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We aimed to evaluate the expression rates of PD-L1 in GC, and further assess its relationship with mismatch repair (MMR), and human epidermal growth factor receptor 2 (HER2) status.
|
29673110 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data indicated that blocking IL-8 derived from GCMSCs may overcome the immune escape induced by PD-L1 in GC cells and provide a potential strategy to enhance the immunotherapy efficiency in GC.
|
30206229 |
2018 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The clinical implications of MSI status and PD-L1 expression in gastric cancer have not been well-elucidated.
|
29727332 |
2019 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry was performed to detect HLA A/B/C, β2M, CD8, p53, and programmed death-ligand 1 (PD-L1) in the center and invasive margin of the tumor in 395 stage II and III GCs using tissue array method.
|
31620857 |
2019 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Exosomal PD-L1 was an independent prognostic factor in GC (n = 69, 95% confidence interval = 1.142-7.669, P = 0.026).
|
31087180 |
2019 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overall, PD-L1 polymorphisms and protein expression were associated with the prognosis of patients with GC.
|
30353572 |
2019 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that tumor PD-L1 positivity was associated with loss of ARID1A and showed trend toward better survival of patients with various molecular subtypes of GC (experimental set, n = 273).
|
30664822 |
2019 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of PD-L1 in GC tissues was analyzed immunohistochemically.
|
31372044 |
2019 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
By using a panel of PD-L1-expressing human GC cell lines and PD-L1-overexpressing cells, we studied cellular uptake, cytotoxic effects, and cellular apoptosis in the presence of PD-L1 mAb-conjugated NPs.
|
30587982 |
2019 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Aim:</b> PD-L1 monoclonal antibody-conjugated miR-130a/oxaliplatin-loaded immunoliposomes were constructed for enhanced therapeutic efficacy against gastric cancer.
|
31290727 |
2019 |